title: [Locoregional immunotherapy of malignant effusions for colorectal cancer using OK-432 and its acting mechanisms--possibility of molecular diagnosis using TCRCDR 3 sequence].
abstract: Locoregional administration using OK-432 was evaluated in treating malignant effusion. Positive clinical responses were seen in 19 (52%) of 36 gastric cancer patients, and in 9 (90%) of 10 colon cancer patients (p < 0.05), indicating its clinical benefit in treating malignant effusion of colon cancer. Fever elevation was observed in 43 (93%) patients and local pain occurred with 9 (20%) of 46 administrations. Immunological analysis for responder patients with rectal cancer revealed that OK-432 induced autologous tumor-reactive CD 3+ CD 4+ TCRV beta 20+ killer lymphocytes. The TCR gene analysis permitted us to clone a V beta 20 CDR 3 sequence, by which positive bands were shown in 3 (75%) of 4 responders and negative bands in 3 (100%) of 3 non-responders. It is suggested that cross-antigenicity exists between OK-432 and colon cancer, and that genetic analysis using the TCRCDR 3 sequence makes it possible to predict responder patients to OK-432 immunotherapy.
authors.affiliation: Dept. of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University.
authors.forename: Y
authors.initials: Y
authors.lastname: Yamaguchi
authors.forename: A
authors.initials: A
authors.lastname: Sawamura
authors.forename: K
authors.initials: K
authors.lastname: Minami
authors.forename: E
authors.initials: E
authors.lastname: Miyahara
authors.forename: T
authors.initials: T
authors.lastname: Toge
mesh_terms: D018528:ATP-Binding Cassette Transporters / Q000235:genetics; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001202:Ascitic Fluid / Q000188:drug therapy; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D022801:Complementarity Determining Regions / Q000235:genetics; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D010844:Picibanil / Q000627:therapeutic use*; D016066:Pleural Effusion, Malignant / Q000188:drug therapy; D011948:Receptors, Antigen, T-Cell; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013274:Stomach Neoplasms / Q000188:drug therapy
chemical_list: D018528:ATP-Binding Cassette Transporters; D000970:Antineoplastic Agents; D022801:Complementarity Determining Regions; D011948:Receptors, Antigen, T-Cell; D010844:Picibanil